Patents by Inventor GAVIN HA

GAVIN HA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260341408
    Abstract: In some embodiments, a computer-implemented method of enhancing sequence read data from a cell-free DNA (cfDNA) sample from a subject for predicting a pregnancy-related condition is provided. A computing system determines a coverage profile based on sequence read data for a plurality of informative sites associated with specific tissue types, cell types, or cell states. The computing system generates a prediction of a presence of or an absence of the pregnancy-related condition by providing at least features from a set of features based on a predicted fetal fraction and a set of features based on the coverage profile as input to at least one machine learning model trained to predict a probability of future onset of the pregnancy-related condition based on the features. In some embodiments, a computer-implemented method of enhancing sequence read data for predicting fetal fraction is provided.
    Type: Application
    Filed: August 25, 2023
    Publication date: October 29, 2026
    Applicants: FRED HUTCHINSON CANCER CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Mohamed ADIL, Gavin HA, Jonathan Brett REICHEL, Christina M. LOCKWOOD, Raj SHREE
  • Publication number: 20250316385
    Abstract: Small cell lung cancer (SCLC) exhibits distinct molecular subtypes characterized by activation of transcription factors (TFs) such as ASCL1, NEUROD1, POU2F3, and REST, but clinical translation has been limited by tissue scarcity. Here, a cell-free DNA (cfDNA) targeted sequencing assay is disclosed that analyzes DNA fragmentation patterns to infer nucleosome profiles at TF binding sites and gene transcription start sites (TSSs) and also detects exonic mutations in certain genes. Application to plasma cfDNA from SCLC patient-derived xenograft models faithfully captured signatures of TF activity and gene expression and revealed a subset of highly informative nucleosome profiling loci including TSSs of key genes including ATOH1, POU2AF2, and targets of SCLC subtype defining TFs. Prediction models of ASCL1, NEUROD1, and REST activity achieved AUCs (0.82-1.00) in SCLC patient samples while a predictor of SCLC vs NSCLC histology achieved an AUC of 0.99.
    Type: Application
    Filed: April 3, 2025
    Publication date: October 9, 2025
    Applicant: Fred Hutchinson Cancer Center
    Inventors: David MacPherson, Joseph Hiatt, Gavin Ha, Anna-Lisa Doebley
  • Publication number: 20230416841
    Abstract: A method of treating prostate cancer based on determining genome-wide methylation profile at a plurality of transcription factor binding sites in the total DNA obtained from cell-free biological samples from a subject suffering from prostate cancer are provided herein. Also described are methods for determining suitable treatment regimens for prostate cancer and methods for treating prostate cancer patients, based around selection of the patients according to the methods of the disclosure. The disclosure also relates to computer-implemented methods for identifying, diagnosing, staging, or otherwise characterizing cancers, in particular advanced prostate cancer. The methods of the present disclosure relate, inter alia, to isolating and analyzing the human DNA component from cell-free samples.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 28, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Michael Haffner, Brian Hanratty, Mohamed Adil, Gavin Ha
  • Patent number: 11479878
    Abstract: The invention provides methods of using low coverage sequencing to assess the relative fraction of tumor versus normal DNA in a sample, and to assess copy number alterations present in the sample.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 25, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Gavin Ha, Viktor Adalsteinsson, Samuel Freeman
  • Publication number: 20190078232
    Abstract: The invention provides methods of using low coverage sequencing to assess the relative fraction of tumor versus normal DNA in a sample, and to assess copy number alterations present in the sample.
    Type: Application
    Filed: March 16, 2017
    Publication date: March 14, 2019
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: GAVIN HA, VIKTOR ADALSTEINSSON, SAMUEL FREEMAN